Sugi Predict

Sugi Predict / Compounds / SCHEMBL5000594

SCHEMBL5000594

SCHEMBL5000594

CC(C)(C)c1ccccc1OCC(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.67
▸ PTGDR2 Q9Y5Y4 2/20 0.62
▸ L3MBTL1 Q9Y468 2/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ POLB P06746 1/20 0.61
▸ GLA P06280 1/20 0.61
▸ KDM4E B2RXH2 4/20 0.59
▸ ALDH1A1 P00352 4/20 0.59
▸ GAA P10253 2/20 0.59
▸ RXRA P19793 1/20 0.59
▸ RXRB P28702 1/20 0.59
▸ RXRG P48443 1/20 0.59
▸ NAMPT P43490 1/20 0.58
▸ ALOX15 P16050 2/20 0.53
▸ TDP1 Q9NUW8 3/20 0.53
▸ HPGD P15428 1/20 0.53
▸ ATM Q13315 1/20 0.51
▸ CYP2C19 P33261 1/20 0.50
▸ RBP4 P02753 2/20 0.49
▸ MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10339023 0.89 L3MBTL1 (0.61) NPSR1PTGDR2L3MBTL1SMN1; SMN2POLB
SCHEMBL2046228 0.85 L3MBTL1 (0.60) NPSR1PTGDR2L3MBTL1SMN1; SMN2POLB
SCHEMBL29755017 0.84 NPSR1 (0.57) NPSR1PTGDR2SMN1; SMN2POLBKDM4E
SCHEMBL7898212 0.84 NPSR1 (0.57) NPSR1PTGDR2SMN1; SMN2POLBKDM4E
SCHEMBL4855773 0.84 NPSR1 (0.57) NPSR1PTGDR2SMN1; SMN2POLBKDM4E
SCHEMBL17847376 0.83 L3MBTL1 (0.54) NPSR1PTGDR2L3MBTL1SMN1; SMN2POLB
SCHEMBL17896576 0.83 PTGDR2 (0.52) NPSR1PTGDR2L3MBTL1SMN1; SMN2POLB
SCHEMBL9060206 0.83 NPSR1 (0.56) NPSR1PTGDR2L3MBTL1GLAKDM4E
SCHEMBL10154342 0.83 NPSR1 (0.59) NPSR1KDM4EALDH1A1GAARXRA
SCHEMBL6699939 0.82 L3MBTL1 (0.57) NPSR1PTGDR2L3MBTL1SMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210147466-A1 IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF TEVA CZECH INDUSTRIES S.R.O. (CZ) 2021-05-20 — — US claimed
EP-3634972-A2 IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF Teva Czech Industries s.r.o. (CZ) 2020-04-15 — — EP claimed
WO-2019014286-A2 IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF TEVA CZECH INDUSTRIES S.R.O. (CZ) 2019-01-17 — — WO claimed
EP-0324917-A1 Low plate-out polycarbonates GENERAL ELECTRIC COMPANY (US) 1989-07-26 — — EP claimed
CN-117813004-A Auxin herbicide and application method thereof 科迪华农业科技有限责任公司 2024-04-02 — — CN disclosed
US-20240051975-A1 NOVEL NAMPT ENZYME AGONIST AND PREPARATION AND USE THEREOF TSINGHUA UNIVERSITY (CN) 2024-02-15 — — US disclosed
CN-114716343-B Novel NAMPT enzyme agonist, preparation and application thereof 清华大学 2023-03-21 — — CN disclosed
CN-114716343-A Novel NAMPT enzyme agonist, preparation and application thereof 清华大学 2022-07-08 — — CN disclosed
WO-2022135617-A1 NOVEL NAMPT ENZYME AGONIST AND PREPARATION AND USE THEREOF 清华大学 2022-06-30 — — WO disclosed
US-20210147466-A1 IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF TEVA CZECH INDUSTRIES S.R.O. (CZ) 2021-05-20 — — US disclosed
US-20200339570-A1 BICYCLIC DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-10-29 — — US disclosed
US-10669268-B2 Bicyclic derivatives HOFFMANN-LA ROCHE INC. (US) 2020-06-02 — — US disclosed
WO-2000037444-A1 COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2000-06-29 — — WO disclosed
EP-0902788-A1 NUCLEOSIDE DERIVATIVES, AND THEIR USE IN OLIGONUCLEOTIDE SYNTHESIS CIS BIO INTERNATIONAL (FR) 1999-03-24 — — EP disclosed
EP-0691959-B1 HETEROCYCLIC DERIVATIVES AS PLATELET AGGREGATION INHIBITORS ZENECA LTD (GB) 1998-07-22 — — EP disclosed
EP-0825184-A1 Heterocyclic derivatives as platelet aggregation inhibitors ZENECA LIMITED (GB) 1998-02-25 — — EP disclosed
WO-1997042207-A1 NUCLEOSIDE DERIVATIVES, AND THEIR USE IN OLIGONUCLEOTIDE SYNTHESIS CIS BIO INTERNATIONAL (FR) 1997-11-13 — — WO disclosed
US-4252952-A 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1981-02-24 — — US disclosed
US-4178445-A 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1979-12-11 — — US disclosed
US-4039536-A 7-(α-SUBSTITUTED GLYCINAMIDO)-3-SUBSTITUTED METHYL-3-CEPHEM-4-CARBOXYLIC ACIDS AND THEIR DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JA) 1977-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051975-A1 NOVEL NAMPT ENZYME AGONIST AND PREPARATION AND USE THEREOF NAMPT, NAT1, SIRT1 NPSR1 215/4885PTGDR2 2175/4885L3MBTL1 4295/4885
US-10669268-B2 Bicyclic derivatives CCNY, BICRA, UQCRB NPSR1 481/4885PTGDR2 558/4885L3MBTL1 3453/4885
US-20200339570-A1 BICYCLIC DERIVATIVES CCNY, BICRA, UQCRB NPSR1 481/4885PTGDR2 558/4885L3MBTL1 3453/4885
US-20210147466-A1 IMPROVED PROCESSES FOR THE PREPARATION OF GUADECITABINE AND INTERMEDIATES THEREOF UNG, SAMHD1, ALKBH1 NPSR1 4832/4885PTGDR2 3707/4885L3MBTL1 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.